Chitosan Derivative Dissolves Biofilms, Reduces Mucus Viscosity and Enhances the Antibacterial Power of Tobramycin September 14, 2011 — Synedgen, Inc. announces new research results demonstrating that its proprietary chitosan derivative, SYN01, effectively dissolves biofilms, reduces mucus viscosity, and maintains broad antibiotic activity against Pseudomonas aeruginosa, a common cause of lung infection associated with cystic fibrosis. [...]
Biotech Firm Synedgen Announces Research Results Demonstrating Significant Antimicrobial Activity against Food-borne pathogens by its lead Chitosan Derivative
Chitosan Derivatives Reduce E. coli and coliform concentrations in models of food contamination July 13, 2011 — New research conducted jointly between Synedgen, Inc., and the School of Environment, Natural Resources and Geography, at Bangor University, Bangor, UK demonstrates that a novel biocompatible and bactericidal chitosan derivative developed by Synedgen offers a rapid and safe [...]
Biotech Firm Synedgen Announces Research Results of New Antibacterial Wound Treatment
Wound Rinse Removes Bacteria and Biofilms Without Damaging Tissue May 20, 2011 — Synedgen will report recent data from its studies of a new wound rinse at a poster session May 23 at ASM 2011, the annual meeting of the American Society for Microbiology in New Orleans. The poster, Novel Antibacterial Chitosan Derivatives with Residual [...]
Synedgen Receives $1.96 million from the NIH to Accelerate the Development of a Promising New Treatment for Oral Mucositis
Treatment is being developed to reduce oral infection and pain associated with cancer treatments March 21, 2011 (Honolulu, HI & Claremont CA) – Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen’s proprietary oral disease treatments. Under this [...]
Synedgen and University of New South Wales Partner to Improve Bone Regeneration
September 30, 2010 — Synedgen and the University of New South Wales will investigate therapies to improve bone growth and wound healing as part of a new project sponsored by the Australian Research Council’s Linkage Project Grants program. [...]
Synedgen Announces Successful Results of NIH-Funded Research into Treatment of Multi-drug Resistant Bacterial Infections in Wounds
September 16, 2010 — Synedgen announced today the completion of a highly successful research study funded by the the National Institutes of Health (NIH) that shows the ability of their wound decontamination rinse to kill highly drug-resistant bacteria. [...]
Shenda Baker Named President of Synedgen, Inc.
Sept. 9, 2010 — Shenda Baker, Ph.D., has been named president and chief operating officer at Synedgen, Inc., a bio-pharmaceutical company committed to developing novel therapies and products to save live in hospitals, on the battlefield, in our food supply and in the home. [...]
Biotech Firm Synedgen Announces Research Results of New Treatment for Oral Disease
May 28, 2010 — Synedgen announced yesterday promising results from its latest study of an oral rinse to reduce gingivitis and prevent oral plaque accumulation. The results were presented May 27 the 110th General Meeting of the American Society for Microbiology in San Diego, Calif. [...]
U.S. Army Awards $2.73 Million To Synedgen for Development of Molecules That Kill Drug-Resistant Bacteria
May 12, 2010 — Synedgen, Inc. has been awarded $2.73 million in funding by the U.S. Army for development of life-saving products and therapies to treat drug-resistant bacteria, particularly those that threaten U.S. troops injured in the battlefield. The award will be used to [...]
Hawaii Biotech Firm Receives NIH Funding to Accelerate the Development of a New Wound Treatment
May 3, 2010 — Synedgen, Inc. has been awarded a competitive SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen’s proprietary Wound Decontamination Rinse that targets multi-drug resistant bacteria and the thick mucus-like biofilms they form. Contaminated wounds are becoming extremely difficult to treat, particularly when infected with drug [...]